A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

What Was Tested

The trial (phase 3) is built around Semaglutide and Mazdutide.

It had two arms (groups): Semaglutide (active comparator) and IBI362 (experimental).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 349 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Male or female, age 18 years or older at the time of signing informed consent. T2D was diagnosed according to WHO standards in 1999(≤5 years). Have a BMI ≥28 kg/m2.

The full record lists 4 inclusion and 8 exclusion criteria; among the exclusions: subjects who the investigator thinks may be allergic to the components in the study drug or similar drugs; oral hypoglycemic drugs other metformin have been used within 2 months before screening; previous diagnosis of type 1 diabetes (including adult latent autoimmune diabetes).

How the Study Was Run

Design: randomized, parallel-group and open-label.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Nothing was hidden in this open-label Semaglutide study: the participants and staff both knew the treatment.

It started in 2024-02-29 with completion listed for 2025-09-17.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

It also tracked 21 secondary outcomes, for example Change from Baseline in HbA1c, Change in fasting plasma glucose(FPG) from baseline, Change in 7-point self-monitored blood glucose(SMBG) from baseline, Change in body weight from baseline, Percent change in body weight from baseline and Change in waist circumference from baseline.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Semaglutide and Mazdutide in 349 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page and the Mazdutide compound page, all human trials.